Menu
Menu
We’re excited to celebrate Genos Médica, a leader in genetic and genomic medicine in Mexico, as they expand their collaboration with SOPHiA GENETICS to further their research using the SOPHiA DDM™ Platform.
Genos Médica is adopting SOPHiA DDM™ Exhanced Whole Exome and Liquid Biopsy applications to strengthen its research capabilities in rare disease and oncology, empowering its teams to uncover new insights that support the growth of precision medicine across Mexico and Latin America.
“Our collaboration withSOPHiA GENETICS allows us to explore the full potential of genomic data through cutting-edge applications like whole exome and liquid biopsy. These technologies will help advance our research efforts and expand the understanding of genetic variation in diverse populations.” said Dr. Melania Abreu González, Medical Geneticist, Genos Médica
At SOPHiA GENETICS, we’re proud to partner with research and clinical institutions worldwide that share our vision: democratizing data-driven medicine and accelerating discovery for a healthier future.
🔗 Learn more about our enhanced exome solutions here: https://www.sophiagenetics.com/sophia-ddm-for-genomics/inherited-disorders/sophia-ddm-enhanced-exome-solutions
We’re thrilled to welcome Seguros SURA Colombia to the SOPHiA GENETICS community as they adopt MSK-ACCESS® powered by SOPHiA DDM™ to advance their precision oncology research initiatives.
As one of Latin America’s leading healthcare organizations, Seguros SURA Colombia is recognized for its commitment to driving innovation and research that strengthens the healthcare ecosystem. By implementing this cutting-edge liquid biopsy solution for research purposes, SURA is empowering its teams to generate insights that will help advance precision medicine initiatives in Colombia and across the region.
“We are excited to integrate MSK-ACCESS® powered by SOPHiA DDM™ into our Omics Sciences Center. This platform will enable us to deepen our understanding of cancer biology and contribute to the growth of precision medicine in Colombia.” Said Carlos Andrés Agudelo, Manager of the Biosciences Center, Seguros SURA Colombia
At SOPHiA GENETICS, our mission is to democratize data-driven medicine worldwide by giving healthcare and research institutions access to powerful, AI-enabled analytics that transform complex data into meaningful insights. We’re proud to partner with Seguros SURA Colombia as they take this important step toward advancing precision oncology research across the region.
Here’s to expanding access to innovation and accelerating research for better outcomes.
Learn more about MSK-ACCESS® powered with SOPHiA DDM™: https://www.sophiagenetics.com/sophia-ddm-for-genomics/liquid-biopsy/msk-access/
SOPHiA GENETICS is proud to participate in the 50th National Congress of the Mexican Association of Human Genetics (AMGH) and the 9th Latin American Congress of Human Genetics, organized by AMGH and the Red Latinoamericana de Genética Humana.
📅 November 12–14, 2025
📍 Hotel Sheraton Buganvilias, Puerto Vallarta, Jalisco, Mexico
As a global leader in data-driven medicine, we are thrilled to join this milestone event, bringing together experts, researchers, and clinicians from across Latin America.
📍 Visit us at Booth 6
Our team will be on-site to showcase how the SOPHiA DDM™ Platform transforms complex genomic data into actionable insights—empowering healthcare professionals to accelerate discovery, enhance diagnosis, and drive precision medicine forward.
SOPHiA GENETICS is proud to participate in the Congreso Latinoamericano de Patología 2025, taking place in Santiago, Chile.
📍 Visit us at Booth S5
Our team will be on-site to showcase how SOPHiA GENETICS is transforming pathology and laboratory medicine with data-driven insights. Explore our latest innovations across Liquid Biopsy, Solid Tumors, Hematologic Malignancies, and more—empowering clinicians and researchers to advance precision medicine in Latin America.
We look forward to connecting with the pathology community in Santiago and sharing how our technology is shaping the future of healthcare.
We’re excited to be part of the 36th Brazilian Congress of Medical Genetics, joining experts, researchers, and clinicians from Brazil. Our focus this year is on presenting the most recent launch — SOPHiA DDM™ Enhanced Exome Solutions. Visit us at booth #3 to learn how our technology can empower your work in medical genetics.
Discover cutting-edge insights with this on-demand session from the ACGH Congress. Dr. Carlos Santamaría, Head of the Molecular Diagnostics Division at the National Children’s Hospital in Costa Rica, shares real-world experiences with exome sequencing in a national pediatric setting. Followed by Dr. Sevana Yaghoubian, Global Director of Genomics at SOPHiA GENETICS, presenting the SOPHiA DDM™ Exome Enhanced Solutions and their impact on clinical decision-making
SOPHiA GENETICS is proud to participate in the 70th Anniversary of the SBG Congress, taking place in Belém, Brazil, in 2025. As a global leader in data-driven medicine, we are thrilled to engage with the genetics and healthcare communities at this landmark event.
📍 Visit us at Booth #5
Our team will be on-site to showcase how SOPHiA GENETICS is transforming complex genomic data into actionable insights—empowering clinicians and researchers worldwide.
Discover the New Generation SOPHiA DDM™ Platform
Explore our most recent innovations in Exome Sequencing, and learn how they are advancing the diagnosis and resolution of complex genetic cases.
Save the date! Corporate Workshop
Date: August 15
Time: 1:00 pm - 2:00 pm
Hangar 2 Room
Title: Unraveling Complex Genetic Disorders via Exome Sequencing
Speakers:
Dra. Ilana Zalcberg Renault, Onco-hematologist, Dasa Genômica
Bruno Piovezan, Subject Matter Expert, SOPHiA GENETICS
📣Exciting news! We are thrilled to welcome Argenetics Lab to our global community. The Argentinian company is a leader in genomics testing, offering comprehensive genomic solutions and solving all laboratory processes locally.
The lab will use our comprehensive, end-to-end application to further chronic lymphoma leukemia (CLL) research, allowing Argenetics to enter into the complex field of blood-derived cancers and becoming the first in Argentina to adopt this advanced NGS technology.
“Our interest in Sophia Genetics is founded on their team's unparalleled expertise, technical precision, validation processes, optimized NGS workflow and powerful analytics platforms. We are particularly excited to implement their CLL application to streamline workflows for oncohematologists and support healthcare providers,” said
Gabriela Norese (https://www.linkedin.com/in/gabriela-norese-906308a9/), Medical Director at Argenetics lab (https://www.linkedin.com/company/laboratorio-argenetics/posts/?feedView=all).
This adoption of SOPHiA DDM™ into the Argentinian market has the potential to advance data-driven medicine and provide professionals with an expanded range of testing options to support their work.
"We are honored to work with Argenetics to support the adoption of data-driven medicine into Argentina, helping to bring world-class NGS testing to support healthcare researchers and clinicians who are working to improve outcomes for patients throughout Latin America,” said Ricardo Ramos Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS.
Learn more about our solutions for blood cancers like leukemia here: https://www.sophiagenetics.com/clinical/oncology/blood-cancers/lymphoid-malignancies/
We’re proud to announce that Bioma Genetics, a leading precision medicine center in Brazil, has expanded its partnership with SOPHiA GENETICS by adopting the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution.
This advanced application enables the accurate identification of HRR gene mutations and genomic instability, providing researchers with comprehensive insights into HRD status.
By integrating this solution, BIOMA GENETICS enhances its capabilities in personalized oncology care, particularly for cancers where HRD is a critical biomarker.
With this expansion, BIOMA GENETICS continues to be part of the growing global network of over 800 institutions leveraging SOPHiA DDM™ to streamline complex variant analysis and strengthen precision medicine across oncology and inherited diseases.
Learn more about our HRD solution: https://lnkd.in/dSY_CAdu
SOPHiA GENETICS is excited to join the ACGH 2025 Congress in Cartagena, Colombia! Meet us at booth #15 to discover the latest innovations of the New Generation SOPHiA DDM™ Platform, with a special focus on Exome advancements. This event is a key milestone for the scientific and academic community, reinforcing Colombia’s leadership in human genetics. Let’s shape the future of genomics together!
Save the date! Sponsored Academic Lunch
June 12th | 1:00-2:00pm | Room 3
Title
From Data to Diagnosis: The Impact of Enhanced Exomes in Precision Medicine
Speakers
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.